Topics

Innoviva, Inc. Company Profile

10:56 EST 27th January 2020 | BioPortfolio

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc., including the closed triple combination therapy for COPD. For more information, please visit Innoviva's website at www.inva.com.


News Articles [8 Associated News Articles listed on BioPortfolio]

GSK, Innoviva file sNDA to seek US approval for Trelegy Ellipta in asthma

Trelegy Ellipta, which is a once-daily, single-inhaler triple therapy, was approved by the US Food and Drug Administration (FDA) in late 2017 for the long-term, once-daily maintenance treatment The p...

Innoviva Inc. Is A Buy

GlaxoSmithKline, Innoviva announce marketing application for Trelegy Ellipta in the US for adults with asthma http://bit.ly/2nXgejl  $GSK #FDA #pharma

GlaxoSmithKline, Innoviva announce marketing application for Trelegy Ellipta in the US for adults with asthma http://bit.ly/2nXgejl  $GSK #FDA #pharma

GSK Submits sNDA to the FDA for Trelegy Ellipta for Use in Patients With Asthma

LONDON–(BUSINESS WIRE)–GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (...

Innoviva Reports Second Quarter 2019 Financial Results

Total net revenue decreased by 4% to $64.1 million in the second quarter of 2019, compared to the same quarter in 2018. Income before income taxes decreased slightly to $56.5 million in the second...

Innoviva Reports Third Quarter 2019 Financial Results

Total net revenue increased by 7% to $65.8 million in the third quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 15% to $57.6 million in the third qua...

GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma

GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional indicat...

Progenity Strengthens Executive Team with the Addition of Eric d’Esparbes as Chief Financial Officer

Progenity, Inc., a privately held biotechnology company, today announced the hire of Eric d’Esparbes as Senior Vice President and Chief Financial Officer (CFO). Mr. d’E...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Innoviva, Inc.

Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and finan...

More Information about "Innoviva, Inc." on BioPortfolio

We have published hundreds of Innoviva, Inc. news stories on BioPortfolio along with dozens of Innoviva, Inc. Clinical Trials and PubMed Articles about Innoviva, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Innoviva, Inc. Companies in our database. You can also find out about relevant Innoviva, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...


Corporate Database Quicklinks



Searches Linking to this Company Record